Program

The Best of ASCO Program presents the scientific and educational highlights of the ASCO Annual Meeting selected from the year’s notable abstracts.

Friday

7:00 AM-3:00 PM Exhibits Open
7:00 AM-7:55 AM Registration and Complimentary Continental Breakfast
7:55 AM-8:00 AM

Welcome and Chair Remarks

Ann H. Partridge, MD, MPH, FASCO
Dana-Farber Cancer Institute

8:00 AM-9:40 AM

Genitourinary Cancers

Ravi A. Madan, MD
National Cancer Institute
Genitourinary (Prostate) Cancer
 

Abstract 5000: A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial. (Pirkko-Liisa Kellokumpu-Lehtinen)

 

Abstract 5001: 68Ga-PSMA11 PET/CT localizes recurrent prostate cancer with high accuracy: Preliminary results from a phase 2/3 prospective trial. (Wolfgang Fendler)

 

Abstract 5003: Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized Phase II trial. (Noel Clarke)

 

Abstract 5007: KEYNOTE-199: pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). (Johann De Bono)



M. Dror Michaelson, MD, PhD
Massachusetts General Hospital
Genitourinary (Nonprostate) Cancer
 

Abstract LBA3: CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial. (Arnaud Mejean)

 

Abstract 4500: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): results from cohort A of KEYNOTE-427. (David McDermott)

 

Abstract 4503: First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt). (Arlene Siefker-Radtke)

 

Abstract 4511: Patient-reported outcomes (PROs) in IMmotion151: atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC). (Bernard Escudier)



Panel Question and Answer

9:40 AM-10:00 AM Break
10:00 AM-11:40 AM

Breast Cancer

Tiffany Traina,  MD
Memorial Sloan Kettering Cancer Center
Breast Cancer—Local/Regional/Adjuvant
 

Abstract LBA1: TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node negative breast cancer and an intermediate prognosis 21-gene recurrence score. (Joseph Sparano)

 

Abstract 104: Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). (Sibylle Loibl)

 

Abstract 500: Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial. (Michael Gnant)

 

Abstract 506: PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. (Helena Earl)



Beverly Moy, MD
Massachusetts General Hospital
Breast Cancer—Metastatic
 

Abstract 1000: Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from MONALEESA-3. (Dennis Slamon)

 

Abstract 1005: Everolimus (EVE) + Exemestane (EXE) vs EVE Alone or Capecitabine (CAP) for Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2-negative (HER2-) Advanced Breast Cancer (ABC): BOLERO-6, an Open-label Phase 2 Study. (Guy Jerusalem)

 

Abstract LBA1006: Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. (Jose Baselga)

 

Abstract 1007: AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. (Peter Schmid)



Panel Question and Answer

11:40 AM-12:15 PM

Legislative and Regulatory Update: Practice Management and Policy Issues

Continue the conversation by networking with Faculty at the Legislative Update Networking Roundtables with Complimentary Boxed Lunch. 

12:15 PM-1:15 PM

Legislative Update Networking Roundtables
With Complimentary Boxed Lunch

12:15 PM- 1:15 PM Complimentary Boxed Lunch
1:15 PM-2:00 PM

Patient and Survivor Care

Shoshana Rosenberg, ScD
Dana-Farber Cancer Institute
Patient and Survivor Care
 

Abstract 10000: Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). (Sherry Shen)

 

Abstract 10001: The effect of acupuncture versus cognitive behavior therapy on insomnia in cancer survivors: A randomized clinical trial. (Jun Mao)

 

Abstract LBA10003: Improving Communication with Older Patients with Cancer using Geriatric Assessment (GA): A University of Rochester NCI Community Oncology Research Program (NCORP) Cluster Randomized Controlled Trial (CRCT). (Supriya Mohile)

 

Abstract 10005: Randomized Trial of a Symptom Monitoring Intervention for Hospitalized Patients with Cancer.(Charn-Xin Fuh)



Question and Answer

2:00 PM-2:40 PM

Hematologic Malignancies

William Blum, MD
Emory University
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
 

Abstract 103: Impact of Next-Generation Sequencing (NGS) on Treatment Selection in Acute Myeloid Leukemia (AML). (Rita Assi)

 

Abstract 7000: Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study. (Daniel Pollyea)

 

Abstract 7004: Moxetumomab Pasudotox in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia: Results of a Pivotal International Study. (Robert Kreitman)

 

Abstract 7010: Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML). (Courtney Dinardo)

2:40 PM-3:00 PM Break
3:00 PM-4:40 PM

Hematologic Malignancies, Continued

TBD
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
 

Abstract 7500: RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma.(Nathan Fowler)

 

Abstract 7501: Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM). (Roger Owen)

 

Abstract 7502: Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL). (William Wierda)

 

Abstract 7505: Updated Safety & Long Term Clinical Outcomes in TRANSCEND NHL 001, Pivotal Trial of Lisocabtagene Maraleucel (JCAR017) in R/R Aggressive NHL. (Jeremy Abramson)



Irene M. Ghobrial, MD
Dana-Farber Cancer Institute
Hematologic Malignancies—Plasma Cell Dyscrasia
 

Abstract 8000: Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W. (Maria-Victoria Mateos)

 

Abstract 8003: Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's Macroglobulinemia. (Meletios Dimopoulos)

 

Abstract 8004: Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. (Luciano Costa)

 

Abstract 8008: FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response. (Aviva Krauss)



Panel Question and Answer